http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 May 2026 17:41:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26529691.html si-local-file:///var/storage/secattach/20260520/26529691.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26529691.html Wed, 20 May 2026 17:41:00 -0400 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26529691.html si-local-file:///var/storage/secattach/20260520/26529691.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26529691.html Wed, 20 May 2026 17:41:00 -0400 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CalciMedica%2C+Inc.+++++++++For%3A+Mar+31/26477922.html si-local-file:///var/storage/secattach/20260512/26477922.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CalciMedica%2C+Inc.+++++++++For%3A+Mar+31/26477922.html Tue, 12 May 2026 16:11:00 -0400 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CalciMedica%2C+Inc.+++++++++For%3A+Mar+31/26477922.html si-local-file:///var/storage/secattach/20260512/26477922.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CalciMedica%2C+Inc.+++++++++For%3A+Mar+31/26477922.html Tue, 12 May 2026 16:11:00 -0400 CALC O.28976467 http://www.streetinsider.com/Earnings/CalciMedica+%28CALC%29+Misses+Q1+EPS+by+30c/26473904.html <p>CalciMedica (NASDAQ: CALC) reported Q1 EPS of ($0.30).</p><p>For earnings history and earnings-related data on CalciMedica (CALC) <a href="http://www.streetinsider.com/ec_earnings.php?q=CALC">click here</a>.</p> http://www.streetinsider.com/Earnings/CalciMedica+%28CALC%29+Misses+Q1+EPS+by+30c/26473904.html Tue, 12 May 2026 08:41:56 -0400 CALC http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html <div class="xn-content"> <p class="prntac"><i>FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 </i></p><p class="prntac"><i>Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+%26amp%3B+Corporate+Updates/26472705.html Tue, 12 May 2026 07:00:00 -0400 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CalciMedica%2C+Inc.+++++++++For%3A+May+12/26472760.html si-local-file:///var/storage/secattach/20260512/26472760.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CalciMedica%2C+Inc.+++++++++For%3A+May+12/26472760.html Tue, 12 May 2026 07:00:00 -0400 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CalciMedica%2C+Inc.+++++++++For%3A+May+12/26472760.html si-local-file:///var/storage/secattach/20260512/26472760.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CalciMedica%2C+Inc.+++++++++For%3A+May+12/26472760.html Tue, 12 May 2026 07:00:00 -0400 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Soleus+Private+Equity+Fund+III%2C+L.P./26462250.html si-local-file:///var/storage/secattach/20260508/26462250.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Soleus+Private+Equity+Fund+III%2C+L.P./26462250.html Fri, 08 May 2026 17:01:00 -0400 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Soleus+Private+Equity+Fund+III%2C+L.P./26462250.html si-local-file:///var/storage/secattach/20260508/26462250.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Soleus+Private+Equity+Fund+III%2C+L.P./26462250.html Fri, 08 May 2026 17:01:00 -0400 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++CalciMedica%2C+Inc.+++++++++For%3A+Dec+31/26407280.html si-local-file:///var/storage/secattach/20260430/26407280.html http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++CalciMedica%2C+Inc.+++++++++For%3A+Dec+31/26407280.html Thu, 30 Apr 2026 16:01:00 -0400 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++CalciMedica%2C+Inc.+++++++++For%3A+Dec+31/26407280.html si-local-file:///var/storage/secattach/20260430/26407280.html http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++CalciMedica%2C+Inc.+++++++++For%3A+Dec+31/26407280.html Thu, 30 Apr 2026 16:01:00 -0400 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CalciMedica%2C+Inc.+++++++++For%3A+Apr+05++Filed+by%3A+Roberts+Eric+W/26284742.html si-local-file:///var/storage/secattach/20260407/26284742.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CalciMedica%2C+Inc.+++++++++For%3A+Apr+05++Filed+by%3A+Roberts+Eric+W/26284742.html Tue, 07 Apr 2026 21:50:00 -0400 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CalciMedica%2C+Inc.+++++++++For%3A+Apr+05++Filed+by%3A+Roberts+Eric+W/26284742.html si-local-file:///var/storage/secattach/20260407/26284742.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CalciMedica%2C+Inc.+++++++++For%3A+Apr+05++Filed+by%3A+Roberts+Eric+W/26284742.html Tue, 07 Apr 2026 21:50:00 -0400 CALC O.28976467